ArticleRheumatology international2024
Monitoring disease activity and treatment response in ankylosing spondylitis: a retrospective study of hematologic inflammatory markers.
Article in Rheumatology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Peripheral blood cell dynamics during biological therapy in axial spondyloarthritis: association between lymphocytosis and treatment response.Clinical rheumatology · 2026Article
- Fibrinogen-to-Platelet Ratio and Hematologic Inflammatory Indexes in Spondylarthritis.Journal of clinical medicine · 2026Article
- Hematological Indices as Potential Biomarkers of Disease Activity in Ankylosing Spondylitis: LASSO-Based Multivariable Modelling.Medicina (Kaunas, Lithuania) · 2026Observational
- Changes in hematological indices during adalimumab therapy in ankylosing spondylitis: a one-year retrospective study.Reumatologia · 2026Article
- Clinical evidence and implementation guidance for biosimilar switching in ankylosing spondylitis.Frontiers in pharmacology · 2026Review
- Advancing Gouty Arthritis Research: The Clinical Value of Complete Blood Cell Count Ratios and Immune-Inflammatory Interactions.Journal of inflammation research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHematological markers such as the neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR), and platelet-lymphocyte ratio (PLR) are reliable indicators of inflammation. This study aims to investigate the potential role of these markers in assessing disease activity and treatment response in biologic-naive Ankylosing Spondylitis (AS) patients following the initiation of biological agents. MATERIALS AND
methodsWe designed this study as a retrospective cohort study with data obtained from a single center. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and The Bath Ankylosing Spondylitis Functional Index (BASFI) were used to evaluate disease activity and functional status of AS patients. Laboratory results at baseline, 3rd, 6th, and 12th months were documented. We calculated hematologic inflammatory markers for each visit. Mean platelet volume (MPV) and red cell distribution width (RDW) were also noted.
results54 biologic-naive patients with AS were included in this study. These inflammatory markers, except RDW, decreased over time. BASDAI, BASFI, CRP and ESR were significantly lower at 3rd, 6th, and 12th months compared to baseline values (all p < 0.001). Furthermore, NLR, PLR, and MLR showed a statistically significant decrease at 3rd, 6th, and 12th months compared to baseline values (all p < 0.001). However, when comparing the values at the 3rd, 6th, and 12th months, no statistically significant differences were observed. We also found no correlation between hematological inflammatory markers and BASDAI scores, despite observing some correlations between hematological markers and acute phase reactants.
conclusionThese markers could be valuable assessment tools for indicating disease activity and monitoring patients with AS after initiating biological treatment.
Indexed as
Identifiers
39733134What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.